Amryt Pharma is a commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing treatments for rare diseases. Co.'s portfolio is comprised of commercial rare disease products, as well as a development-stage pipeline focused on rare skin diseases. Co.'s commercial products include: lomitapide for the treatment of homozygous familial hypercholesterolemia; metreleptin for the treatment of generalized lipodystrophy and partial lipodystrophy; and Mycapssa® (octreotide capsules), which is approved in the U.S. for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. The AMYT average annual return since 2020 is shown above.
The Average Annual Return on the AMYT average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether AMYT average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AMYT average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|